Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases

Rosén, C. ; Mattsson, N. ; Johansson, Per LU orcid ; Andreasson, U. ; Wallin, A. ; Hansson, Oskar LU orcid ; Johansson, J.-O. ; Lamont, J. ; Svensson, J. and Blennow, K. , et al. (2011) In Frontiers in Aging Neuroscience 3.
Abstract
The role of biomarkers in neurodegenerative diseases has been emphasized by recent research. Future clinical demands for identifying diseases at an early stage may render them essential. The aim of this pilot study was to test the analytical performance of two multiplex assays of cerebral markers on a well-defined clinical material consisting of patients with various neurodegenerative diseases. We measured 10 analytes in plasma and cerebrospinal fluid (CSF) from 60 patients suffering from Alzheimer's disease (AD), vascular dementia, frontotemporal dementia, dementia with Lewy bodies, or mild cognitive impairment, as well as 20 cognitively healthy controls. We used the Randox biochip-based Evidence Investigator™ system to measure the... (More)
The role of biomarkers in neurodegenerative diseases has been emphasized by recent research. Future clinical demands for identifying diseases at an early stage may render them essential. The aim of this pilot study was to test the analytical performance of two multiplex assays of cerebral markers on a well-defined clinical material consisting of patients with various neurodegenerative diseases. We measured 10 analytes in plasma and cerebrospinal fluid (CSF) from 60 patients suffering from Alzheimer's disease (AD), vascular dementia, frontotemporal dementia, dementia with Lewy bodies, or mild cognitive impairment, as well as 20 cognitively healthy controls. We used the Randox biochip-based Evidence Investigator™ system to measure the analytes. We found it possible to measure most analytes in both plasma and CSF, and there were some interesting differences between the diagnostic groups, although with large overlaps. CSF heart-type fatty acid-binding protein was increased in AD. Glial fibrillary acidic protein and neutrophil gelatinase-associated lipocalin in CSF and D-dimer in plasma were elevated in patients with cerebrovascular disease. A multivariate statistical analysis revealed that the pattern of analytes could help to differentiate the conditions, although more studies are required to verify this. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer, Biochip, Fatty acid-binding protein, Neurodegenerative diseases
in
Frontiers in Aging Neuroscience
volume
3
publisher
Frontiers Media S. A.
external identifiers
  • scopus:84859731075
  • pmid:21442044
ISSN
1663-4365
DOI
10.3389/fnagi.2011.00001
project
Endocrine and diagnostic aspects of cognitive impairment
language
English
LU publication?
yes
additional info
JAN
id
78e99691-ea8a-4c90-9ae5-09c64e13fd41 (old id 8510456)
alternative location
http://www.scopus.com/inward/record.url?eid=2-s2.0-84859731075&partnerID=MN8TOARS
date added to LUP
2016-04-04 09:45:30
date last changed
2025-02-17 18:23:51
@article{78e99691-ea8a-4c90-9ae5-09c64e13fd41,
  abstract     = {{The role of biomarkers in neurodegenerative diseases has been emphasized by recent research. Future clinical demands for identifying diseases at an early stage may render them essential. The aim of this pilot study was to test the analytical performance of two multiplex assays of cerebral markers on a well-defined clinical material consisting of patients with various neurodegenerative diseases. We measured 10 analytes in plasma and cerebrospinal fluid (CSF) from 60 patients suffering from Alzheimer's disease (AD), vascular dementia, frontotemporal dementia, dementia with Lewy bodies, or mild cognitive impairment, as well as 20 cognitively healthy controls. We used the Randox biochip-based Evidence Investigator™ system to measure the analytes. We found it possible to measure most analytes in both plasma and CSF, and there were some interesting differences between the diagnostic groups, although with large overlaps. CSF heart-type fatty acid-binding protein was increased in AD. Glial fibrillary acidic protein and neutrophil gelatinase-associated lipocalin in CSF and D-dimer in plasma were elevated in patients with cerebrovascular disease. A multivariate statistical analysis revealed that the pattern of analytes could help to differentiate the conditions, although more studies are required to verify this.}},
  author       = {{Rosén, C. and Mattsson, N. and Johansson, Per and Andreasson, U. and Wallin, A. and Hansson, Oskar and Johansson, J.-O. and Lamont, J. and Svensson, J. and Blennow, K. and Zetterberg, H.}},
  issn         = {{1663-4365}},
  keywords     = {{Alzheimer; Biochip; Fatty acid-binding protein; Neurodegenerative diseases}},
  language     = {{eng}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Aging Neuroscience}},
  title        = {{Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases}},
  url          = {{http://dx.doi.org/10.3389/fnagi.2011.00001}},
  doi          = {{10.3389/fnagi.2011.00001}},
  volume       = {{3}},
  year         = {{2011}},
}